China NMPA Drug Inspection - Jilin Fukang Pharmaceutical Co., Ltd. - Lung-boosting tablets

On May 15, 2020, the Chongqing Municipal Drug Administration announced the findings of a quality supervision inspection that identified 28 batches of non-compliant drugs produced by 18 different companies. Key manufacturers named in the report include Liangshan Xinxin Traditional Chinese Medicine Pieces Co., Ltd., Sichuan Gukang Pharmaceutical Co., Ltd., and Jilin Daojun Pharmaceutical Co., Ltd. The inspections revealed several significant quality violations. These included failures in content determination (incorrect levels of active ingredients), substandard dissolution rates for Ibuprofen sustained-release capsules, and excessive impurity levels. Furthermore, several traditional herbal products were found to be moldy, insect-infested, or failed microscopic identification and weight consistency tests. These evaluations were conducted under the regulatory framework of the 2010 and 2015 editions of the Chinese Pharmacopoeia and the 2006 Chongqing Municipal Standards for Processing Traditional Chinese Medicine. In response to these findings, the administration has ordered immediate regulatory actions, including the sealing and seizure of substandard products, the suspension of sales, and mandatory product recalls. The involved companies will face legal processing in accordance with national regulations to ensure public safety and maintain pharmaceutical market integrity.